DYNAVAX TECHNOLOGIES CORP (DVAX) Stock Fundamental Analysis
USA - NASDAQ:DVAX - US2681582019 - Common Stock
10.83 USD
-0.16 (-1.46%)
10.83 USD
0 (0%)
Overall DVAX gets a fundamental rating of 5 out of 10. We evaluated DVAX against 535 industry peers in the Biotechnology industry. DVAX has an average financial health and profitability rating. DVAX is not overvalued while it is showing excellent growth. This is an interesting combination.
1. Profitability
1.1 Basic Checks
DVAX had positive earnings in the past year.
In the past year DVAX had a positive cash flow from operations.
In multiple years DVAX reported negative net income over the last 5 years.
DVAX had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -5.74%, DVAX belongs to the top of the industry, outperforming 87.31% of the companies in the same industry.
The Return On Equity of DVAX (-10.67%) is better than 88.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.74% | ||
| ROE | -10.67% | ||
| ROIC | N/A |
ROA(3y)10.61%
ROA(5y)3.5%
ROE(3y)17.99%
ROE(5y)-8.35%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
DVAX's Profit Margin has declined in the last couple of years.
DVAX has a better Gross Margin (82.83%) than 86.01% of its industry peers.
DVAX's Gross Margin has improved in the last couple of years.
DVAX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 82.83% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-15.64%
PM growth 5YN/A
GM growth 3Y10.73%
GM growth 5Y12.85%
2. Health
2.1 Basic Checks
DVAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DVAX has been reduced compared to 1 year ago.
The number of shares outstanding for DVAX has been increased compared to 5 years ago.
Compared to 1 year ago, DVAX has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.51, we must say that DVAX is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 1.51, DVAX is doing good in the industry, outperforming 64.37% of the companies in the same industry.
DVAX has a debt to FCF ratio of 3.95. This is a good value and a sign of high solvency as DVAX would need 3.95 years to pay back of all of its debts.
DVAX has a better Debt to FCF ratio (3.95) than 93.10% of its industry peers.
A Debt/Equity ratio of 0.53 indicates that DVAX is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.53, DVAX is doing worse than 72.76% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 3.95 | ||
| Altman-Z | 1.51 |
ROIC/WACCN/A
WACC8.15%
2.3 Liquidity
DVAX has a Current Ratio of 6.65. This indicates that DVAX is financially healthy and has no problem in meeting its short term obligations.
DVAX has a better Current ratio (6.65) than 67.35% of its industry peers.
A Quick Ratio of 6.01 indicates that DVAX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.01, DVAX is in the better half of the industry, outperforming 63.99% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.65 | ||
| Quick Ratio | 6.01 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 211.54% over the past year.
The earnings per share for DVAX have been decreasing by -19.10% on average. This is quite bad
DVAX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.36%.
DVAX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 51.10% yearly.
EPS 1Y (TTM)211.54%
EPS 3Y-19.1%
EPS 5YN/A
EPS Q2Q%75%
Revenue 1Y (TTM)19.36%
Revenue growth 3Y-14.23%
Revenue growth 5Y51.1%
Sales Q2Q%17.67%
3.2 Future
The Earnings Per Share is expected to grow by 58.55% on average over the next years. This is a very strong growth
Based on estimates for the next years, DVAX will show a quite strong growth in Revenue. The Revenue will grow by 15.25% on average per year.
EPS Next Y-347.92%
EPS Next 2Y65.78%
EPS Next 3Y58.55%
EPS Next 5YN/A
Revenue Next Year20.52%
Revenue Next 2Y18.53%
Revenue Next 3Y17.48%
Revenue Next 5Y15.25%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 26.41, the valuation of DVAX can be described as expensive.
Based on the Price/Earnings ratio, DVAX is valued cheaply inside the industry as 93.47% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 25.83, DVAX is valued at the same level.
With a Price/Forward Earnings ratio of 21.89, DVAX is valued on the expensive side.
Based on the Price/Forward Earnings ratio, DVAX is valued cheaper than 92.72% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 32.68. DVAX is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.41 | ||
| Fwd PE | 21.89 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, DVAX is valued cheaply inside the industry as 90.67% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, DVAX is valued cheaper than 95.15% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.22 | ||
| EV/EBITDA | 48.65 |
4.3 Compensation for Growth
DVAX's earnings are expected to grow with 58.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y65.78%
EPS Next 3Y58.55%
5. Dividend
5.1 Amount
DVAX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
10.83
-0.16 (-1.46%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners98.07%
Inst Owner Change-0.7%
Ins Owners0.56%
Ins Owner Change-11.93%
Market Cap1.27B
Revenue(TTM)277.25M
Net Income(TTM)-52.73M
Analysts80
Price Target24.48 (126.04%)
Short Float %12.19%
Short Ratio8.51
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-28.28%
Min EPS beat(2)-86.66%
Max EPS beat(2)30.1%
EPS beat(4)3
Avg EPS beat(4)-9.07%
Min EPS beat(4)-86.66%
Max EPS beat(4)30.1%
EPS beat(8)6
Avg EPS beat(8)79.21%
EPS beat(12)9
Avg EPS beat(12)63.09%
EPS beat(16)10
Avg EPS beat(16)25.23%
Revenue beat(2)1
Avg Revenue beat(2)2%
Min Revenue beat(2)-3.96%
Max Revenue beat(2)7.97%
Revenue beat(4)1
Avg Revenue beat(4)-1.56%
Min Revenue beat(4)-6.08%
Max Revenue beat(4)7.97%
Revenue beat(8)3
Avg Revenue beat(8)-0.53%
Revenue beat(12)7
Avg Revenue beat(12)3.41%
Revenue beat(16)9
Avg Revenue beat(16)9.62%
PT rev (1m)0%
PT rev (3m)0.76%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-14.09%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.64%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.43%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.69%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.41 | ||
| Fwd PE | 21.89 | ||
| P/S | 4.02 | ||
| P/FCF | 19.22 | ||
| P/OCF | 16.65 | ||
| P/B | 2.57 | ||
| P/tB | 2.58 | ||
| EV/EBITDA | 48.65 |
EPS(TTM)0.41
EY3.79%
EPS(NY)0.49
Fwd EY4.57%
FCF(TTM)0.56
FCFY5.2%
OCF(TTM)0.65
OCFY6.01%
SpS2.7
BVpS4.21
TBVpS4.2
PEG (NY)N/A
PEG (5Y)N/A
Graham Number6.23
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.74% | ||
| ROE | -10.67% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 82.83% | ||
| FCFM | 20.89% |
ROA(3y)10.61%
ROA(5y)3.5%
ROE(3y)17.99%
ROE(5y)-8.35%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-15.64%
PM growth 5YN/A
GM growth 3Y10.73%
GM growth 5Y12.85%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 3.95 | ||
| Debt/EBITDA | 35.01 | ||
| Cap/Depr | 124.44% | ||
| Cap/Sales | 3.23% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 1023.9% | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.65 | ||
| Quick Ratio | 6.01 | ||
| Altman-Z | 1.51 |
F-Score5
WACC8.15%
ROIC/WACCN/A
Cap/Depr(3y)107.38%
Cap/Depr(5y)141.26%
Cap/Sales(3y)1.68%
Cap/Sales(5y)6.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)211.54%
EPS 3Y-19.1%
EPS 5YN/A
EPS Q2Q%75%
EPS Next Y-347.92%
EPS Next 2Y65.78%
EPS Next 3Y58.55%
EPS Next 5YN/A
Revenue 1Y (TTM)19.36%
Revenue growth 3Y-14.23%
Revenue growth 5Y51.1%
Sales Q2Q%17.67%
Revenue Next Year20.52%
Revenue Next 2Y18.53%
Revenue Next 3Y17.48%
Revenue Next 5Y15.25%
EBIT growth 1Y94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year185.54%
EBIT Next 3Y81.5%
EBIT Next 5YN/A
FCF growth 1Y-55.18%
FCF growth 3Y-43.07%
FCF growth 5YN/A
OCF growth 1Y-49.89%
OCF growth 3Y-41.69%
OCF growth 5YN/A
DYNAVAX TECHNOLOGIES CORP / DVAX FAQ
What is the fundamental rating for DVAX stock?
ChartMill assigns a fundamental rating of 5 / 10 to DVAX.
What is the valuation status for DVAX stock?
ChartMill assigns a valuation rating of 6 / 10 to DYNAVAX TECHNOLOGIES CORP (DVAX). This can be considered as Fairly Valued.
Can you provide the profitability details for DYNAVAX TECHNOLOGIES CORP?
DYNAVAX TECHNOLOGIES CORP (DVAX) has a profitability rating of 4 / 10.
What is the expected EPS growth for DYNAVAX TECHNOLOGIES CORP (DVAX) stock?
The Earnings per Share (EPS) of DYNAVAX TECHNOLOGIES CORP (DVAX) is expected to decline by -347.92% in the next year.